The user base for a Pfizer Inc. therapy aimed at rheumatoid arthritis patients has more than doubled in the past three months.
The drug, Xeljanz, was developed at Pfizer's campus in Groton and received regulatory approval about six months ago.
BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceuticals, said in a news release that 61 percent of rheumatologists surveyed are now trying Xeljanz in their patient populations. This compares with a trial rate of 32 percent three months ago.
Specialists averaged only six patients on Xeljanz, though they anticipated numbers would increase in the future.